Document Detail


Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.
MedLine Citation:
PMID:  23334258     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.
Authors:
Derek J Hausenloy; Hans Erik Bøtker; Gianluigi Condorelli; Peter Ferdinandy; David Garcia-Dorado; Gerd Heusch; Sandrine Lecour; Linda W van Laake; Rosalinda Madonna; Marisol Ruiz-Meana; Rainer Schulz; Joost P G Sluijter; Derek M Yellon; Michel Ovize
Related Documents :
25336468 - Revascularization decisions in patients with stable angina and intermediate lesions: re...
1403238 - Myocardial fibrosis and the concepts of cardioprotection and cardioreparation.
9741358 - Regional activation of the immediate-early response gene c-fos in infarcted rat hearts.
9592028 - Monophosphoryl lipid a reduces both arrhythmia severity and infarct size in a rat model...
20435188 - Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardia...
11295988 - Cerebrovascular reactivity and subcortical infarctions.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-19
Journal Detail:
Title:  Cardiovascular research     Volume:  98     ISSN:  1755-3245     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-18     Completed Date:  2013-09-06     Revised Date:  2014-11-05    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  7-27     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiopulmonary Bypass
Cardiopulmonary Resuscitation
Collateral Circulation
Coronary Artery Bypass
Coronary Circulation
Coronary Disease / complications,  therapy*
Disease Models, Animal
Heart Transplantation
Humans
Myocardial Reperfusion Injury / prevention & control*
Signal Transduction
Grant Support
ID/Acronym/Agency:
FS/06/023//British Heart Foundation; MR/K002066/1//Medical Research Council; RG/08/015/26411//British Heart Foundation; //Department of Health

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Qualitative and quantitative analysis of the unsaponifiable fraction of vegetable oils by using comp...
Next Document:  Flecainide Reduces Ca2+ Spark and Wave Frequency Via Inhibition of The Sarcolemmal Sodium Current.